Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2002

View Archived Issues

Telomerase inhibitors under study at Pharmacia

Novel 5-HT6 ligands for depression, anxiety, cognitive disorders, etc., claimed in recent patent

AstraZeneca team identifies kappa opioid agonists

TLK-286 enters two new combination trials

Amended phase II protocol for FM-VP4

Argenta Discovery and Amedis extend collaboration

Provectus acquires company recently split from Photogen

Milnacipran improves FMS pain and fatigue in preliminary analysis

Phase III Ampligen trial in CFS completes enrollment

Paladin returns Canadian DepoCyt rights to SkyePharma

Pharmexa and Lundbeck Alzheimer's collaboration achieves proof of concept in animals

Minimal toxicity reported for SGN-30 in Hodgkin's disease and lymphoma

Potential use of MLN-518 in AML and high-risk MDS

Significant improvement reported on eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Reduced liver iron content in thalassemic patients treated with ICL-670

Comparison of warfarin and idraparinux sodium in deep vein thrombosis

New cephem antibiotics discovered jointly by Fujisawa and Wakunaga

Series of 5-HT1A antagonists in early development at Wyeth

KuDOS and Maybridge claim isoquinoline-based PARP inhibitors

New tyrosine kinase inhibitors and their use in proliferative disorders

Veronate granted fast track status

Helix BioPharma completes acquisition of minority interest in Sensium

Medicure enters research collaboration with university group for NHE inhibitors

GSK identifies novel 5-HT7 receptor antagonist with good pharmacokinetic properties

Fully human MAb to human VEGFR-3 designed at ImClone Systems

Pharmacological profile of VX-944, an IMPDH inhibitor, characterized at ASH meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...